INTRODUCTION
z Disease modifying drugs such as interferons and glatiramer acetate collectively known as BRACE therapies are commonly used as first line treatment for patients with Relapsing Remitting MultipleSclerosis (RRMS). BRACE therapies include Betaseron − To explore the applicability of novel analytical methods at identifying treatment effect heterogeneity i.e. differences in response to BRACE therapy amongst different types of RRMS patients
METHODS

Study design
z This was a retrospective database analysis using administrative health plan claims data. This included medical and pharmacy data from the IMS PharMetrics Plus Database from the US which was accessed through the MS Value and Evidence in Real wOrld (VERO) platform developed by Novartis z The index window was 1 January 2007 to 31 March 2012 and twelve months continuous enrolment both pre-index and post-index was required The pharmacy claim fails to include valid days supply or quantity/packs dispensed information on any claim for the index therapy during the 12-month follow-up period AND the days supply cannot be imputed using the product detail or package size information.
Study population
Pre-index treatment of either no MS treatment or a different BRACE treatment, i.e., patients were naive to index-specific BRACE treatments ≥1 diagnosis of MS (ICD-9-CM: 340) in the pre-index period *Relapse was defined using an algorithm based on one tested in previous analyses of claims data 
RESULTS
z The study included 3,669 patients that comprised 1,767 responders and 1,902 non-responders, indicating a 51.8% non-response rate. Patients who had at least one pre-index relapse and no post-index relapse were considered to be BRACE responders, whereas patients who had at least one pre-index relapse and at least one post-index relapse were considered to be BRACE non-responders (Table 2) z Approximately, half of the patient population was aged between 34 and 50 and a large proportion (77%) of patients were females (Table 2) z Approximately, 42.8% and 33.1% of patients switched from no pre-index MS treatment to an Interferon and glatiramer acetate, respectively (Table 2) Selection of model and model performance z Model selection was based on several criteria, including maximizing out-of-sample accuracy, model stability, familiarity with choice of method and minimizing overfitting (Table 3) Table  4 Values of AUC associated with discriminatory power of a model z The AUC on training data was higher compared to test data for all the models and it was highest for the random forest model (73) ( Table 5) z The more advanced models (for e.g. SVM with RBF Kernel and Random Forest model) in this study did not lead to markedly improved performance compared to standard logistic regressions (Table 5) z All the AUCs in the test data ranged from 62.3-64.4 indicating moderate predictive accuracy (Table 5 ) Model ability to discriminate BRACE responders and non-responders z Approximately, 73.5% of patients in the highest quintile group did not respond to BRACE therapy compared to 32.8% in the group who were more likely to respond according to quintiles based on predictions from the logistic regression with Lasso ( Figure 2) and Figure 3 shows the patient characteristics associated with being more likely to be BRACE non-responders 
CONCLUSIONS
z The results suggested that patients were least likely to respond to BRACE treatment if they were young and/or had active disease z No single model had optimum performance according to all criteria and the more advanced models did not lead to markedly improved performance compared to standard logistic regressions z Logistic regression with a Lasso penalty was selected as the preferred model and it was able to discriminate between who are likely to respond and not respond to BRACE therapy z The results suggested that medical claims data can provide some insight on treatment non-response but highly accurate models may require richer clinical information z Predictive modelling can support treatment decision making by identifying patients that could benefit from escalation switches
